Kenvue Inc. (KVUE)vsVertex Pharmaceuticals Inc (VRTX)
KVUE
Kenvue Inc.
$17.66
+0.63%
CONSUMER DEFENSIVE · Cap: $33.73B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Kenvue Inc. generates 26% more annual revenue ($15.12B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 9.7%. KVUE appears more attractively valued with a PEG of 1.49. VRTX earns a higher WallStSmart Score of 66/100 (B-).
KVUE
Buy58
out of 100
Grade: C
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.3%
Fair Value
$18.79
Current Price
$17.66
$1.13 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
3.2% revenue growth
Weak financial health signals
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KVUE
PEG of 1.49 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : KVUE
The primary concerns for KVUE are Revenue Growth, Piotroski F-Score, Altman Z-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
KVUE profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
KVUE carries more volatility with a beta of 0.47 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
KVUE generates stronger free cash flow (744M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 58/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kenvue Inc.
CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA
Kenvue Inc. is a consumer health company globally.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other HOUSEHOLD & PERSONAL PRODUCTS Stocks
Want to dig deeper into these stocks?